LungLife AI, Inc. (the “Company” or “LungLife”) LungLife to participate in the US National Cancer Institute’s Early Detection Research Network LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that based on the strength of its technology it will be one of two industry partners to participate in the Boston […]
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2022. Summary and Highlights (including post-period end): Cash as of 30 June 2022 of $10.63m Loss before […]
LungLife AI licensure/accreditation information posted here.